Cardiovascular toxicity of regorafenib for heavily-treated osteosarcoma

Pediatr Int. 2021 Jul;63(7):857-859. doi: 10.1111/ped.14503. Epub 2020 Dec 5.

Authors

Yuya Saito^{1

2}, Atsushi Makimoto³, Masaru Miura⁴, Yuki Yuza²

Affiliations

¹ Departments of, Department of, Pediatrics, Tama-Hokubu Medical Center, Tokyo, Japan.
² Department of, Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
³ Department of, Laboratory Medicine, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
⁴ Department of, Cardiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

PMID: 33277804
DOI: 10.1111/ped.14503

No abstract available

Keywords: congestive heart failure; osteosarcoma; regorafenib.

MeSH terms

Antineoplastic Agents* / adverse effects
Colorectal Neoplasms*
Humans
Osteosarcoma* / drug therapy
Phenylurea Compounds / adverse effects
Pyridines / adverse effects

Substances

Antineoplastic Agents
Phenylurea Compounds
Pyridines
regorafenib